Fig. 2From: Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi ArabiaThe mean rates (%) of disability progression, clinical relapse, and new lesions on MRI for patients on ocrelizumab, natalizumab, and rituximabBack to article page